Literature DB >> 23438721

Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.

T Pal1, J-H Lee, A Besharat, Z Thompson, A N A Monteiro, C Phelan, J M Lancaster, K Metcalfe, T A Sellers, S Vadaparampil, S A Narod.   

Abstract

BRCA testing services are now offered by various healthcare providers, thus it is important to evaluate whether the implementation of cancer risk management (CRM) strategies varies by service provider. Using a registry-based sample of 795 female BRCA mutation carriers, we explored the association between uptake of CRM strategies with duration of genetic counseling (GC) sessions, provider type, and other demographic and clinical variables. All participants completed a baseline questionnaire. Information about uptake of CRM strategies was collected for a subset of 438 participants who completed additional questions. Summary statistics and Pearson chi-squared analysis were used to examine the associations between demographic and clinical variables with service delivery factors and with the uptake of various CRM strategies. Overall uptake of CRM strategies was high across all provider types. However, GC sessions were longer when provided by a genetics professional than by another provider (p < 0.001). Furthermore, higher frequencies of uptake of most CRM strategies were associated with longer GC sessions and when testing was performed by a genetics professional. Identification of factors to optimize delivery of these specialized GC services is important to maximize implementation of CRM strategies in BRCA carriers.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BRCA; clinical practice delivery; genetic counseling; genetic testing

Mesh:

Substances:

Year:  2013        PMID: 23438721      PMCID: PMC4519074          DOI: 10.1111/cge.12130

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

Review 1.  Prevention and management of hereditary breast cancer.

Authors:  Steven A Narod; Kenneth Offit
Journal:  J Clin Oncol       Date:  2005-03-10       Impact factor: 44.544

Review 2.  American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.

Authors:  Mark E Robson; Courtney D Storm; Jeffrey Weitzel; Dana S Wollins; Kenneth Offit
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

Review 3.  Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications.

Authors:  Karina L Brierley; Erica Blouch; Whitney Cogswell; Jeanne P Homer; Debbie Pencarinha; Christine L Stanislaw; Ellen T Matloff
Journal:  Cancer J       Date:  2012 Jul-Aug       Impact factor: 3.360

4.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

5.  Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.

Authors:  Bronson D Riley; Julie O Culver; Cécile Skrzynia; Leigha A Senter; June A Peters; Josephine W Costalas; Faith Callif-Daley; Sherry C Grumet; Katherine S Hunt; Rebecca S Nagy; Wendy C McKinnon; Nancie M Petrucelli; Robin L Bennett; Angela M Trepanier
Journal:  J Genet Couns       Date:  2011-12-02       Impact factor: 2.537

Review 6.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

7.  Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians.

Authors:  L Wideroff; S T Vadaparampil; M H Greene; S Taplin; L Olson; A N Freedman
Journal:  J Med Genet       Date:  2005-03-22       Impact factor: 6.318

Review 8.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

9.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

10.  Physicians' experiences with BRCA1/2 testing in community settings.

Authors:  Nancy L Keating; Kathryn A Stoeckert; Meredith M Regan; Lisa DiGianni; Judy E Garber
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

View more
  17 in total

1.  Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals.

Authors:  Cristi Radford; Anya Prince; Karen Lewis; Tuya Pal
Journal:  J Genet Couns       Date:  2013-12-04       Impact factor: 2.537

2.  Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.

Authors:  Anita Y Kinney; Laurie E Steffen; Barbara H Brumbach; Wendy Kohlmann; Ruofei Du; Ji-Hyun Lee; Amanda Gammon; Karin Butler; Saundra S Buys; Antoinette M Stroup; Rebecca A Campo; Kristina G Flores; Jeanne S Mandelblatt; Marc D Schwartz
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

3.  Models of service delivery for cancer genetic risk assessment and counseling.

Authors:  Angela M Trepanier; Dawn C Allain
Journal:  J Genet Couns       Date:  2013-10-26       Impact factor: 2.537

Review 4.  Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities.

Authors:  Kathleen F Mittendorf; Sarah Knerr; Tia L Kauffman; Nangel M Lindberg; Katherine P Anderson; Heather Spencer Feigelson; Marian J Gilmore; Jessica Ezzell Hunter; Galen Joseph; Stephanie A Kraft; Jamilyn M Zepp; Sapna Syngal; Benjamin S Wilfond; Katrina A B Goddard
Journal:  JCO Precis Oncol       Date:  2021-11-03

5.  Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.

Authors:  Hidetaka Nomura; Masayuki Sekine; Shiro Yokoyama; Masami Arai; Takayuki Enomoto; Nobuhiro Takeshima; Seigo Nakamura
Journal:  Int J Clin Oncol       Date:  2019-05-04       Impact factor: 3.402

6.  Evolution of Hereditary Breast Cancer Genetic Services: Are Changes Reflected in the Knowledge and Clinical Practices of Florida Providers?

Authors:  Deborah Cragun; Courtney Scherr; Lucia Camperlengo; Susan T Vadaparampil; Tuya Pal
Journal:  Genet Test Mol Biomarkers       Date:  2016-08-15

7.  Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.

Authors:  Adam H Buchanan; Corrine I Voils; Joellen M Schildkraut; Catherine Fine; Nora K Horick; P Kelly Marcom; Kristi Wiggins; Celette Sugg Skinner
Journal:  J Genet Couns       Date:  2016-06-06       Impact factor: 2.537

8.  Differences in BRCA counseling and testing practices based on ordering provider type.

Authors:  Deborah Cragun; Lucia Camperlengo; Emily Robinson; Meghan Caldwell; Jongphil Kim; Catherine Phelan; Alvaro N Monteiro; Susan T Vadaparampil; Thomas A Sellers; Tuya Pal
Journal:  Genet Med       Date:  2014-06-12       Impact factor: 8.822

Review 9.  Alternate Service Delivery Models in Cancer Genetic Counseling: A Mini-Review.

Authors:  Adam Hudson Buchanan; Alanna Kulchak Rahm; Janet L Williams
Journal:  Front Oncol       Date:  2016-05-13       Impact factor: 6.244

10.  How, who, and when: preferences for delivery of genome sequencing results among women diagnosed with breast cancer at a young age.

Authors:  Kimberly A Kaphingst; Jennifer Ivanovich; Ashley Elrick; Rebecca Dresser; Cindy Matsen; Melody S Goodman
Journal:  Mol Genet Genomic Med       Date:  2016-10-24       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.